TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01262768

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion Size Measurement Aids (PSMAs)
Description: Subjects are randomly assigned to receive either 2D or 3D PSMAs to examine accuracy, acceptability and usefulness of the models. Both groups receive brief instructions on the use of the respective PSMAs, complete an accuracy estimation task, and are given the 2D or 3D PSMAs to take home with them to use for 2-4 weeks, after which the researchers telephone parents to complete a brief satisfaction and usefulness survey.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Portion Size Measurement Aids (PSMAs)
Description: Subjects are randomly assigned to receive either 2D or 3D PSMAs to examine accuracy, acceptability and usefulness of the models. Both groups receive brief instructions on the use of the respective PSMAs, complete an accuracy estimation task, and are given the 2D or 3D PSMAs to take home with them to use for 2-4 weeks, after which the researchers telephone parents to complete a brief satisfaction and usefulness survey.
Study: NCT01469182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCH 39641
Description: Rapidly dissolving tablet sublingually once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for SCH 39641
Description: Rapidly dissolving tablet sublingually once daily
Study: NCT03562130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: Daily sub cutaneous injection 0,05 mg/kg/day
Study: NCT02114164

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AirSeal System
Description: To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endopath
Description: This group receives the Standard Endopath Trocar for intraoperative insufflation.
Study: NCT00096785

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: entecavir
Description: Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adefovir
Description: Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks
Study: NCT01867060

Intervention type: DEVICE
Group type: OTHER
Intervention: Automated Cardiac Event Recorder
Description: Automated Cardiac Event Recorder to be worn continuously for one week.

Intervention type: DEVICE
Group type: OTHER
Intervention: Personal Heart Rhythm Monitor
Description: Personal Heart Rhythm Monitor to be used twice-daily for three months.
Study: NCT03134742

Intervention type: OTHER
Intervention: Control Group
Description: No interventions this is the control group-no additional scans

Intervention type: DIAGNOSTIC_TEST
Intervention: CT Scan
Description: CT Scan of affected and contralateral limb

Intervention type: DIAGNOSTIC_TEST
Intervention: DEXA Scans
Description: DEXA Scan of affected and contralateral limb

Intervention type: DIAGNOSTIC_TEST
Intervention: CT and DEXA Scans
Description: CT Scan and DEXA Scan of affected and contralateral limb
Study: NCT03982836

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble Dietary Fibers
Description: All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soluble Dietary Fibers
Description: All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soluble Dietary Fibers
Description: All 25 volunteers received, were separated for 7 days of washout, one containing maltodextrin (control), Frutooligossacharide or guar gum partially hydrolyzed in a randomized manner. As the partially hydrolyzed guar gum and fructooligosaccharide, soluble dietary fibers that present different behaviors in the body.
Study: NCT03119961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SONOCLOUD®
Description: BBB opening by ultrasound
Study: NCT00257725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B-MPH
Description: Dosage form is a 20 mg capsule to be given once daily in the morning for 30 days
Study: NCT02573870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batefenterol + Fluticasone Furoate
Description: Batefenterol and Fluticasone Furoate (FF) will be provided as a fixed-dose combination in a dry powder inhaler (DPI), for oral inhalation once every morning, for 42 days. The DPI will consist of 2 strips of 30 blisters each, containing 300 microgram (mcg) batefenterol per blister in one strip and 100 mcg FF per blister in another strip. Both drugs will be available in a micronized form, blended with lactose monohydrate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be provided in a DPI, for oral inhalation once every morning, for 42 days. The DPI will consist of 2 matching strips of 30 blisters each, with each blister containing lactose monohydrate and no active pharmaceutical ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol
Description: Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.
Study: NCT02792270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric Restriction Diet
Description: Two nutritional supplements, one from Ensure (Abbott Laboratories, Chicago, IL) and one from Boost (Nestle, Vevey, Switzerland) will be used for 3 days before surgery.~The supplements are the Ensure Pre-Surgery Clear Carbohydrate Drink and the Ensure Original Nutrition Powder. The Original Nutrition Powder will be mixed with 8oz of water, oat milk, or almond milk. The proposed macronutrient profile for the 3 days of caloric restriction (CR) is less than 8% of calories from protein.
Study: NCT02751203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Make Safe Happen App
Description: The Make Safe Happen app is a mobile app (available for free download android and iOS) developed by the safety experts in the Center for Injury Research and Policy. Parents and caregivers can use the app to learn how to make their homes safer with room-to-room safety checklists and links to recommended products. App users can also create to-do lists, set reminders and track their progress.
Study: NCT04483674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide
Description: Patients will be administered one pill of 50mg bictegravir/200mg emtricitabine/25mg tenofovir alafenamide daily for 48 weeks with regular check-ups at weeks 4,8,12,24 and 48 including:~* complete physical examination~* register concomitant medication~* blood test~* concomitant medications~* assessment od adverse events~* assessement of compliance~* PSQI and CESTA questionnaire (week 4 and 48)~* Recommendation in contraception methods~* Stool sample and pregnancy test urine (week 0 and 48)~The total of blood required for each visit is 30ml except the visit of week 48 (90ml) The total of urine required is 6 mL
Study: NCT03707067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Compression garments
Description: Made-to-measure compression garments providing high pressures (\> 30 mmHg at the ankle and \>20 mmHg at the thigh - equivalent to European class-2 stockings)

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham recovery drink
Description: Non-caloric beverage, labelled as a recovery drink proposed to enhance athletic recovery. Aspartame/acesulfame-k based sweetener, providing 0.5 g carbohydrate and 2 Kcal per serving
Study: NCT02440360

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PSH
Description: Please see arm description.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Please see arm description.
Study: NCT03642756

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: different intra-arterial catheter size
Description: in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: different intra-arterial catheter size
Description: in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: different intra-arterial catheter size
Description: in placebo group, patients were cannulated with 20 gauge intra-arterial catheter. In experiment groups, patients were cannulated with 22 gauge or 24 gauge intra-arterial catheter.
Study: NCT01419951

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinic + Home Behavioral Intervention
Description: A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pediatrician Counseling
Description: A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Only Behavioral Intervention
Description: A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
Study: NCT04405154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Administered as an intravenous (IV) infusion every 2 weeks (Q2W): 14 days prior to radiation, then Day 1 of radiation and then every 14 days for total 8 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75-100 mg/m\^2 administered as an IV infusion Q3W, for a total of 3 doses, at the same time as radiation: Day 1, Day 22, Day 43 of radiation.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT or VMAT
Description: 66-70 Gy given in 33-35 fractions over 6-7 weeks.
Study: NCT03218098

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lobectomy via UVATS
Description: lobectomy with small skin access 4 cm

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lobectomy via UVATS
Description: lobectomy with small skin access 4 cm
Study: NCT00986544

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: no drain
Description: drain positioned on the skin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: drain positioned
Description: drain positioned in the subhepatic space

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: drain not positioned
Description: Drain positioned in the abdominal wall
Study: NCT03896542

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Commercial video game.
Description: Stroke patient had played with commercial video game, along 12 sessions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rehabilitation video game
Description: Stroke patient had played with an specific video game for rehabilitation, along 12 sessions
Study: NCT01825057

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: See One
Description: A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Do One
Description: A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop training, providers conduct two motivational interviews bedside with patients under the supervision of one of the MI-trained CL clinicians, who subsequently give them performance feedback and coaching. Providers receive one more supervised practice case mid-trial. In addition, they can request additional supervision at any point during the trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Order One
Description: A 1-day workshop conducted by a member of the Motivational Interviewing Network of Trainers (MINT), according to MINT recommendations, to build providers' skills needed to use MI with patients who misuse substances. Following the workshop, providers have the option to conduct MI with patients themselves or to order a MI for delivery by one of the MI-trained CL clinicians.
Study: NCT03831061

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Study: NCT02187172

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00547872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise testing - coronary angiography - revascularization
Description: Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
Study: NCT01792921

Intervention type: BEHAVIORAL
Intervention: COG - FUN
Study: NCT02177396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study: NCT03324906

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
Study: NCT03485248

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot Juice
Description: 140ml of Beetroot Juice containing on avarege 9 mmol of nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140ml of Beetroot Juice (nitrate free)
Study: NCT01345136

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001, everolimus
Description: Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
Study: NCT00929877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KETOPROFEN(RP19583)
Description: Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KETOPROFEN(RP19583)
Description: Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
Study: NCT03593850

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music group
Description: The song was composed on a C major scale and a 60 bpm tempo. The song was composed with high consonance using simple melodic progressions on the C major scale, and using natural positions for chords. No percussion or lyrics were used for the song, and the following instruments were used in the composition: electric guitar and keyboards, violin (digital), cello (digital), clarinet (digital), synthesizers (digital), and fretless bass (digital).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Silence Group
Description: Audio file that contained no sounds.
Study: NCT00003895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16 E7:12-20
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV 16 E7:12-20
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:209-217(210M)
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: gp100:209-217(210M)
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00415857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (PR1 Peptide)
Description: PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptide Vaccine (PR1 Peptide)
Description: PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b
Description: Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Continue receiving imatinib by mouth at the same dose received during the last 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Continue receiving imatinib by mouth at the same dose received during the last 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
Study: NCT03357315

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mix vaccine
Description: Each treatment: 0.5 ml /week, Subcutaneous injection of the deltoid muscle
Study: NCT05138042

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryotherapy (frozen glove)
Description: In this study, the cryotherapy interventions were based on previous studies, with the dominant hand wearing the frozen glove set as the experimental group, and the non-dominant hand that was not wearing a frozen glove as the control group.~The cold temperature of the refrigerator was measured in advance to be -20.2°C to -22.8°C. The freezing of the gloves lasted for at least three hours, and the gloves were tested with an infrared temperature-measuring instrument before use. Its temperature range was -24.3°C to -24.7°C. The patient began to wear gloves 15 minutes before the administration of paclitaxel for one hour, and replaced them with new frozen gloves at the 45th minute. The patient continued to wear the gloves until 15 minutes after the end of the chemotherapy drug administration, for a total of 90 minutes.
Study: NCT01380730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Evolocumab
Description: Administered by subcutaneous injection